Filing Details
- Accession Number:
- 0000950170-24-077402
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2024-06-25 17:03:15
- Reporting Period:
- 2024-06-24
- Accepted Time:
- 2024-06-25 17:03:15
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1658247 | Crinetics Pharmaceuticals Inc. | CRNX | Pharmaceutical Preparations (2834) | 263744114 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1948238 | Dana Pizzuti | C/O Crinetics Pharmaceuticals, Inc. 6055 Lusk Boulevard San Diego CA 92121 | Chief Med And Dev Officer | No | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2024-06-24 | 9,500 | $16.89 | 37,286 | No | 4 | M | Direct | |
Common Stock | Disposition | 2024-06-24 | 9,500 | $45.73 | 27,786 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock option (Right to Buy) | Disposition | 2024-06-24 | 9,500 | $0.00 | 9,500 | $19.73 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
167,792 | 2032-10-10 | No | 4 | M | Direct |
Footnotes
- The common stock was sold by the reporting person in open market transactions on the transaction date, with a volume weighted average sales price of $45.73 per share. The range of sales prices on the transaction date was $45.53 to $45.88 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
- The option is exercisable as follows: 25% of the shares subject to the option vest on September 30, 2023, and the remaining number of shares subject to the option vest monthly thereafter in thirty-six equal monthly installments, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.